CRISPR-Cas9-Mediated Correction of TSC2 Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2.

IF 3.7 4区 生物学 Q2 GENETICS & HEREDITY
Gongbo Guo, Morgan Moser, Lincoln Chifamba, Dominic Julian, Samantha Teierle, Prajwal Rajappa, Cecelia Miller, Mark E Hester
{"title":"CRISPR-Cas9-Mediated Correction of <i>TSC2</i> Pathogenic Variants in iPSCs from Patients with Tuberous Sclerosis Complex Type 2.","authors":"Gongbo Guo, Morgan Moser, Lincoln Chifamba, Dominic Julian, Samantha Teierle, Prajwal Rajappa, Cecelia Miller, Mark E Hester","doi":"10.1089/crispr.2024.0079","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either the <i>TSC1</i> or <i>TSC2</i> genes. Though TSC causes the formation of nonmalignant tumors throughout multiple organs, the most frequent causes of mortality and morbidity are due to neurological complications. In two-thirds of cases, TSC occurs sporadically and <i>TSC2</i> pathogenic variants are approximately three times more prevalent than <i>TSC1</i> pathogenic variants. Here, we utilized CRISPR-Cas9-mediated homology directed repair in patient induced pluripotent stem cells (iPSCs) to correct two types of <i>TSC2</i> pathogenic variants generating two isogenic lines. In one line, we corrected a splice acceptor variant (c.2743-1G>A), which causes the skipping of coding exon 23 and subsequent frameshift and introduction of a stop codon in coding exon 25. In the second line, we corrected a missense variant in coding exon 40 within the GTPase-activating protein domain (c.5228G>A, p.R1743Q). The generation of TSC2 patient iPSCs in parallel with their corresponding CRISPR-corrected isogenic lines will be an important tool for disease modeling applications and for developing therapeutics.</p>","PeriodicalId":54232,"journal":{"name":"CRISPR Journal","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CRISPR Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/crispr.2024.0079","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either the TSC1 or TSC2 genes. Though TSC causes the formation of nonmalignant tumors throughout multiple organs, the most frequent causes of mortality and morbidity are due to neurological complications. In two-thirds of cases, TSC occurs sporadically and TSC2 pathogenic variants are approximately three times more prevalent than TSC1 pathogenic variants. Here, we utilized CRISPR-Cas9-mediated homology directed repair in patient induced pluripotent stem cells (iPSCs) to correct two types of TSC2 pathogenic variants generating two isogenic lines. In one line, we corrected a splice acceptor variant (c.2743-1G>A), which causes the skipping of coding exon 23 and subsequent frameshift and introduction of a stop codon in coding exon 25. In the second line, we corrected a missense variant in coding exon 40 within the GTPase-activating protein domain (c.5228G>A, p.R1743Q). The generation of TSC2 patient iPSCs in parallel with their corresponding CRISPR-corrected isogenic lines will be an important tool for disease modeling applications and for developing therapeutics.

crispr - cas9介导的2型结节性硬化症患者iPSCs中TSC2致病变异的校正
结节性硬化症(TSC)是由TSC1或TSC2基因突变引起的常染色体显性遗传病。虽然TSC可在多个器官形成非恶性肿瘤,但最常见的死亡和发病原因是神经系统并发症。在三分之二的病例中,TSC是零星发生的,TSC2致病性变异体比TSC1致病性变异体普遍约三倍。在这里,我们利用crispr - cas9介导的同源定向修复在患者诱导的多能干细胞(iPSCs)中纠正两种类型的TSC2致病变异,产生两种等基因系。在一行中,我们纠正了一个剪接受体变异(c.2743-1G> a),该变异导致编码外显子23的跳跃和随后的移码,并在编码外显子25中引入了一个停止密码子。在第二行中,我们纠正了编码gtpase激活蛋白域内第40外显子的错义变异(c.5228G> a, p.R1743Q)。TSC2患者iPSCs的生成及其相应的crispr校正等基因系将成为疾病建模应用和开发治疗方法的重要工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CRISPR Journal
CRISPR Journal Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.30
自引率
2.70%
发文量
76
期刊介绍: In recognition of this extraordinary scientific and technological era, Mary Ann Liebert, Inc., publishers recently announced the creation of The CRISPR Journal -- an international, multidisciplinary peer-reviewed journal publishing outstanding research on the myriad applications and underlying technology of CRISPR. Debuting in 2018, The CRISPR Journal will be published online and in print with flexible open access options, providing a high-profile venue for groundbreaking research, as well as lively and provocative commentary, analysis, and debate. The CRISPR Journal adds an exciting and dynamic component to the Mary Ann Liebert, Inc. portfolio, which includes GEN (Genetic Engineering & Biotechnology News) and more than 80 leading peer-reviewed journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信